Raptor completes patient enrollment for Phase 2/3 clinical trial of RP103

The trial, which involves 96 patients, is being carried out under an agreement with The Centre Hospitalise Universities dangers ("CHI dangers").

The 18-month, double-blind, placebo-controlled study will be followed by an open-label extension study with all patients taking RP103 for up to an additional 18 months.

The primary end point of the clinical trial is based upon the Unified Huntington’s Disease Rating Scale ("UHDRS"). Blood levels of brain-derived neurotrophic factor ("BDNF") are being measured as a secondary endpoint.

RP103 and placebo capsules for the clinical trial and open-label extension study will be supplied by Raptor in turn for regulatory and commercial rights to the result of clinical trials.

CHI dangers M.D.Christophe Verney said,"Having completed enrolment of patients, we are excited to analyse the data and examine the potential of delayed release steaming as a reproductivity for treating Huntington’s Disease.

Raptor holds license to property related to steaming for the potential treatment of Huntington’s Disease from the University of California, San Diego and from the Weizmann Institute of Science in Israel and Japan’s Nougat University.

The expenditure of the clinical trials is borne by the French government funding.